Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escitalopram in Generalized Anxiety Disorder (Russia)
NCT00902564Phase 4Completed
- Sponsor
- Lundbeck
- Start
- Mar 2009
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Escitalopram oxalate oral solution in generalized anxiety disorder (GAD), sponsored by Lundbeck. Primary endpoint: Hamilton Anxiety Scale at 8 weeks. Started Mar 2009; status: completed.
02
Drugs
Escitalopram oxalate oral solution
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT00902564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00902564.